Navigation Links
Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
Date:9/25/2007

Wide-Ranging ZD4054 Phase III Development Program Announced

WILMINGTON, Del., Sept. 25 /PRNewswire-FirstCall/ -- The results from the randomized, double-blind, placebo-controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 -- a specific endothelin A (ETA) receptor antagonist -- were delivered today at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona). The data presented today for ZD4054, an investigational compound in development for the treatment of men with hormone resistant prostate cancer (HRPC), showed no differences in progression free survival (PFS) but did report encouraging overall survival (OS) data.(1)

To further evaluate the potential of ZD4054, the Phase III trial program ENTHUSE (ENDOTHELIN A USE), consisting of three studies, will begin this year. The first of these trials is aimed at investigating the efficacy of ZD4054 in metastatic HRPC, while the second will look at its role in nonmetastatic HRPC patients. A third trial will study ZD4054 in combination with docetaxel (Taxotere(TM)) for the treatment of metastatic HRPC.

Nick James, Professor of Clinical Oncology, Institute for Cancer Studies, Birmingham, UK, and principal investigator of the EPOC study said: "Men with advanced prostate cancer are typically treated with hormonal therapies. Whilst these therapies can provide great benefits, most men will become resistant to them. Currently, the only licensed treatment option for metastatic patients shown to improve survival in men with HRPC is chemotherapy with docetaxel."

"The results from the EPOC study suggest that ZD4054 10 mg once daily may have the potential to increase the median overall survival time for men with asymptomatic or mildly symptomatic metastatic HRPC."

EPOC (Endothelin A Proof Of Concept) Phase II findings:

The primary endpoint of the study was progression free survival (PFS) and a secondary endpoint was Overall Survival (OS). The
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Living in the Unreal World: A Survival Guide for Entrepreneurs
2. The Top 10 Musts That Should Be in Your Business Survival Kit
3. Wisconsin Manufacturing - demise or survival?
4. University Consortium Enables Transformation and Survival for Wisconsin Businesses
5. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
6. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
7. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
8. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
9. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
10. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
11. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...VALLEY, Calif., Nov. 6 Calbiotech,...mall Business Innovative Research (SBIR) Phase I c...rial command. Under terms of the agreement, Calbio... for the diagnosis of Dengue virus. ,, Dengu...nts a major threat to military forces deployed to ...
(Date:11/5/2009)...SBURG, Md., Nov. 5 GenVe...cial results for the third quarter ended September...ion ($0.04 per share) for the three months ended S...illion ($0.08 per share) in the comparable quarter...2009, GenVec,s net loss was $14.1 million ($0.15 p...
(Date:11/5/2009)...nce Call on Thursday, November 5, 2009 at 4:30 p.m...v. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceut...: OGXI ) today reported unaudited financial resul...tember 30, 2009 and reviewed the Company,s highlig...wing consolidated results reflect the operations o...
(Date:11/5/2009)...GO, CA, November 5, 2009 ... on using proprietary taste receptor-based technol... food, beverage, and ingredient supply industries,...nancial results for the third quarter ended Septem...third quarter of 2009, compared to $4.0 million fo...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...er 23 GlaxoSmithKline Biologicals,S.A. (GSK) and ...llaboration agreement granting GSK exclusive right...mes, aimed at treating Alzheimer,s by,targeting be...iring exclusive rights to develop,and commercialis...are based,on AFFiRiS AFFiTOPE technology and are c...
.... 23 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ...cial results for 2008 after the market closes on T...webcast a conference call at 5:00 p.m. EST,2:00 p....live webcast, please log on to the Company,s websi...Information section. Alternatively,domestic caller...
...l April 27, 2009 to Regain Compliance with $1.00 ...USTIN, Calif., Oct. 23 Peregrine,Pharmaceuticals,...ceutical,company developing monoclonal antibodies ...ctions, today announced that it has received a let...ional time to regain,compliance with the minimum b...
Other Biology Technology:GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 2GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 3CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008 2Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule 2
(Date:11/4/2009)...ct. 26 BIO-key Internati... finger-based biometric identification software is...t the AABB TXPO conference being held at the New O...BIO-key will provide hands-on product demonstratio...gy in booth #424. Also, at 5 PM on Monday, October...
(Date:11/4/2009)...if., Nov. 4 GenVault Corporation (...M.D., Ph.D., has joined its Board of Directors. D...he Salk Institute, is an acclaimed physician-scien...Salk Institute, Dr. Brody served as president of T...e National Academy of Engineering and the Institut...
(Date:11/3/2009)...FL (November 4, 2009) For more than 25 years, all... ( Strombus gigas ) have been unsuccessfuluntil no...ng techniques to produce beaded (nucleated) and no... been developed by scientists from Florida Atlanti...te (HBOI). With less than two years of research an...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3iLife Americas LLC Enters U S Wellness and Therapeutic Markets 14561 1iLife Americas LLC Enters U S Wellness and Therapeutic Markets 14561 2Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 1Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 2SemBioSys provides an update on Botaneco 14559 1SemBioSys provides an update on Botaneco 14559 2SemBioSys provides an update on Botaneco 14559 3SemBioSys provides an update on Botaneco 14559 4
...e pet animal, are attractive to owners because of ...re to parrots than what meets the eye. , For more...ts use an unusual set of pigments to produce their...identity has remained elusive. Now, an Arizona Sta...ry behind the colors of parrots, describing on a m...
...Children,s Research,Hospital have discovered that ... bacteria helps these germs invade the human blood...the EMBO Journal, could help,scientists develop a ...otecting children against the disease. The St. Jud...dle-like molecule that,Streptococcus pneumoniae ba...
...l geneticists have found links in the cell death m... for studying and targeting a process vital to dev...iseases. , The work, reported in the February 17 ...dria, the cellular power plant, in prompting worm ...eath models along the evolutionary spectrum, from ...
Other Biology News:ASU researchers finds novel chemistry at work to provide parrot's vibrant red colors 2ASU researchers finds novel chemistry at work to provide parrot's vibrant red colors 3New comparative toxicogenomics database 2New comparative toxicogenomics database 3Critical role in programmed cell death identified 2Critical role in programmed cell death identified 3
A431 cells stimulated with EGF from Exalpha Biologicals, Inc.
...ws graphic manipulation of DNA sequences and sophi...winning interface design that allows graphic manip...sophisticated drawing capabilities for Mac and Win...g Software" by the Biotechnology Software and Inte...
...lances and scales with RS232 ports and sends that ...can type the weight into the program, BalanceTalk ...o use parser extracts required data , Add date/tim...data at timed intervals , Keyboard macros automate...
SlideHyb™ Glass Array Hybridization Survey Kit from Ambion
Biology Products: